Literature DB >> 16506403

Morphometric study on cytoskeletal components of neuronal and astroglial cells after chronic CB1 agonist treatment.

Patricia Tagliaferro1, Alberto J Ramos, Emmanuel S Onaivi, Sergio G Evrard, Maite Duhalde Vega, Alicia Brusco.   

Abstract

One of the major goals for the use of digital image analysis systems in neuroanatomy is to visualize structures, cells, or other tissue components in order to compare various populations. In addition, digital image analysis allows semi-quantification of cell labeling because it is capable of measuring simultaneously the staining intensity, location, size, and shape of labeled profiles. In the present work, the morphological changes in the CB1 hippocampal area and corpus striatum induced by chronic treatment with the synthetic CB1-receptor agonist WIN55,212-2 were analyzed as an example of digital image analysis application. Twice-daily treatment for 14 d with the CB1-receptor agonist demonstrated significant changes in the expression of neuronal cytoskeletal proteins and in neuronal morphology, as evidenced by immunocytochemical and digital analysis studies. However, changes in the expression of astroglial cytoskeletal proteins were not found.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16506403     DOI: 10.1385/1-59259-999-0:91

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  2 in total

1.  Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model.

Authors:  Nadia Stefanova; Biljana Georgievska; Håkan Eriksson; Werner Poewe; Gregor K Wenning
Journal:  Neurotox Res       Date:  2011-12-08       Impact factor: 3.911

2.  Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy.

Authors:  Nadia Stefanova; Walter A Kaufmann; Christian Humpel; Werner Poewe; Gregor K Wenning
Journal:  Acta Neuropathol       Date:  2012-04-11       Impact factor: 17.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.